Japan Syringe Market Size, Share, Opportunities, And Trends By Type (Insulin Syringe, Conventional Syringe), By Material (Glass, Plastic, Stainless Steel), And By Syringe Size (Smaller Volume Syringe, Larger Volume Syringe) - Forecasts From 2023 To 2028

Description

Japan Syringe Market Size:

Japan Syringe Market is projected to grow considerably during the forecast period (2025-2030).

To learn more about this report, request a free sample copy

The Japanese Syringe Market is a highly mature and critical component of the national healthcare infrastructure, uniquely shaped by stringent regulatory oversight, a rapid demographic transition, and advanced domestic pharmaceutical manufacturing. As one of the world's most rapidly aging major economies, Japan presents an escalating demand for injectable drug delivery systems used across hospital, clinic, and growing home healthcare settings. The market's structural evolution is defined by a distinct trade-off: sustained volume from chronic care needs versus a technological imperative for enhanced safety and performance driven by new-generation biologics. This environment requires market participants to maintain an unwavering focus on quality standards defined by the Pharmaceuticals and Medical Devices Agency (PMDA) while aggressively developing highly specialized, pre-filled delivery solutions.

Japan Syringe Market Analysis

• Growth Drivers

The escalating prevalence of non-communicable chronic diseases among the aging population acts as the primary volume driver. Diabetes, rheumatoid arthritis, and various oncological conditions necessitate long-term, routine injectable administration, sustaining the baseline demand for Conventional Syringes in clinical settings. Furthermore, the robust growth in the domestic biologics and biosimilars market, requiring specialized containment and delivery, directly increases demand for Glass Prefillable Syringes. These advanced devices are crucial because they ensure drug stability, offer enhanced patient convenience for self-administration, and provide the pharmaceutical sector with reliable container closure systems for high-value therapies.

• Challenges and Opportunities

A central challenge confronting the market is the competitive displacement effect exerted by alternative delivery technologies. The widespread clinical adoption of Insulin Pens and Autoinjectors for chronic self-injection therapies, valued for their ease of use and dosage accuracy, directly diminishes the market for unspecialized Insulin Syringes. This constraint, however, simultaneously creates a high-margin opportunity: the strict enforcement of safety standards by the MHLW, focused on eliminating occupational exposure to bloodborne pathogens, accelerates the institutional demand shift toward Safety Syringes and auto-retractable mechanisms. Compliance with these safety directives provides a competitive advantage for manufacturers innovating in sophisticated passive safety features.

• Raw Material and Pricing Analysis

The pricing structure for syringes in Japan is fundamentally influenced by the duality of required materials. Plastic Syringes, the high-volume segment, rely on global petrochemical supply for medical-grade polypropylene and polyethylene. Pricing in this segment is highly sensitive to fluctuations in crude oil and polymer manufacturing capacity, placing downward pressure on margins. Conversely, the high-margin Glass segment is defined by the stability and purity of specialized borosilicate glass tubing, which commands a premium due to its critical role in ensuring the shelf-life and efficacy of sensitive biological drugs. This material demand mandates a secure, high-quality domestic or near-shore supply chain to avoid contamination and supply volatility.

• Supply Chain Analysis

The Japanese syringe supply chain is structured to ensure resilience and maintain stringent quality controls, characterized by a dual reliance model. While Japanese corporations like TERUMO and Nipro maintain advanced domestic and regional production centers, particularly for specialized products like Glass Prefillable Syringes, the volume supply of commodity Plastic Syringes often relies on offshore manufacturing hubs, primarily in Southeast Asia and Europe. Logistical complexities involve high-speed sterile packaging, adherence to strict cold chain requirements for pre-filled products, and navigating import regulations under the PMD Act. Key dependencies exist on global specialized material suppliers for high-purity glass and ultra-thin-wall needle cannula.

Japan Syringe Market Government Regulations

Japan Syringe Market Segment Analysis

• By Type: Insulin Syringe

Th need for the classic Insulin Syringe in Japan is characterized by a secular decline, driven by the patient-centric pivot towards Insulin Pens and, increasingly, continuous glucose monitoring (CGM) systems that minimize the need for manual injection preparation. However, a significant, non-displacing niche demand persists. This residual growth is primarily sustained by specific clinical scenarios, such as neonatal care or pediatric patients requiring extremely low, precise dosing volumes (often smaller than a pen-device's minimum click), and in institutional settings where specific clinical dosing protocols preclude pen use. Furthermore, for cost-sensitive patient populations or those with limited access to insurance coverage for premium pen systems, the Insulin Syringe remains a necessary, affordable delivery option, maintaining a stable, albeit shrinking, volume floor within the market. Manufacturers must view this segment as a legacy product, focusing on cost-efficient production rather than innovative development.

• By Material: Glass

The market profile for Glass syringes is intensely linked to the domestic growth of complex injectable pharmaceuticals, particularly high-value biologics, vaccines, and pre-filled emergency medications. The Material segment experiences elevated demand because borosilicate glass offers superior chemical compatibility and gas barrier properties compared to plastic, which is essential for preserving the potency and stability of sensitive protein-based drugs over long shelf lives. The glass material segment is driven by the strict requirement of pharmaceutical companies to minimize extractables, leachables, and silicone oil content (as seen with TERUMO's silicone oil-free products) to prevent protein aggregation. Consequently, the demand for Glass Prefillable Syringes is high-growth and strategically important, as pharmaceutical companies prioritize drug stability and regulatory acceptance over the lower cost of plastic alternatives, thereby commanding a higher unit price and margin in the Japanese market.

Japan Syringe Market Competitive Environment and Analysis

The competitive landscape of the Japan Syringe Market features intense rivalry between globally dominant players (BD, B. Braun) and highly entrenched, quality-focused domestic manufacturers (Nipro, TERUMO). Competition centers on technological sophistication, regulatory compliance capability, and securing large-volume contracts within the national hospital procurement system and major domestic pharmaceutical partnerships. The strategic imperative is to shift the product mix toward pre-filled and safety-engineered devices to capture higher margins in the quality-driven Japanese ecosystem.

• BD (Becton, Dickinson and Company)

BD leverages its global scale and leadership in safety technology to drive demand in the Japanese market, particularly in the premium pre-filled and safety-engineered segments. The company's strategic positioning focuses on pharmaceutical partnerships, supplying high-performance Glass Prefillable Syringes designed for complex drug formulations. A development is the commercial launch of the BD Neopak™ XtraFlow™ Glass Prefillable Syringe, which features a thinner wall cannula to optimize subcutaneous delivery of higher viscosity drugs. This product launch directly supports the expanding Japanese biologics market by addressing the challenge of high injection force and time.

• TERUMO

TERUMO maintains a dominant competitive position in the domestic Japanese market, built on a reputation for high-quality disposable medical products and deep relationships with hospitals and clinics. The company competes across the spectrum, from advanced Conventional Syringes to specialized devices like the PLAJEX™ pre-filled syringe platform. TERUMO's strategy emphasizes technological differentiation in the pre-filled segment, focusing on low-dose and silicone oil-free materials to cater to the sensitive and complex requirements of Japanese pharmaceutical manufacturers for biologic drug stability and patient safety standards.

• Nipro

Nipro is a major Japanese competitor with a focused strategy on increasing its global footprint in the high-growth Glass Prefillable Syringes segment. The company drives demand through its D2F™ (Direct-to-Fill) glass pre-fillable syringe line, positioning itself as a reliable, high-quality packaging partner for the global and Japanese pharmaceutical industries. A key strategic move is the ongoing capacity expansion of its pre-fillable glass syringe production at its German manufacturing facility during 2024, which aims to bolster its supply resilience and service global pharmaceutical partners, including those supplying the stringent Japanese market.

Japan Syringe Market Developments

• November 2025: Kyowa Kirin announced the launch of its Crysvita (burosumab) prefilled syringe formulation in Japan. This new delivery system for the treatment of XLH (X-linked hypophosphatemia) aims to provide greater convenience and ease of administration for patients, potentially enhancing adherence to the chronic treatment.
• July 2025: Celltrion launched Steqeyma® (CT-P43), a biosimilar to ustekinumab (Stelara®), in Japan. This injectable treatment for autoimmune conditions is provided in a syringe format, offering a more cost-effective alternative for conditions like psoriasis and psoriatic arthritis in the Japanese healthcare system.
• September 2024: BD commercially released the Neopak™ XtraFlow™ Glass Prefillable Syringe, which features design enhancements for high-viscosity biologic drugs. Concurrently, BD integrated a high-volume manufacturing line in France, increasing the production capacity of the Neopak™ platform by sevenfold.

Japan Syringe Market Segmentation

• By Type
  • Insulin Syringe
  • Conventional Syringe
    • Eccentric Tip Syringe
    • Catheter Tip Syringe
    • Luer Lock Syringe
• By Material
  • Glass
  • Plastic
  • Stainless Steel
• By Syringe Size
  • Smaller Volume Syringe
  • Larger Volume Syringe

Table Of Contents

1. INTRODUCTION

1.1. Market Overview

1.2. Market Definition

1.3. Scope of the Study

1.4. Market Segmentation

1.5. Currency

1.6. Assumptions

1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY  

2.1. Research Data

2.2. Assumptions

3. EXECUTIVE SUMMARY

3.1. Research Highlights

4. MARKET DYNAMICS

4.1. Market Drivers

4.2. Market Restraints

4.3. Porter’s Five Force Analysis

4.3.1. Bargaining Power of Suppliers

4.3.2. Bargaining Power of Buyers

4.3.3. Threat of New Entrants

4.3.4. Threat of Substitutes

4.3.5. Competitive Rivalry in the Industry

4.4. Industry Value Chain Analysis

5. JAPAN SYRINGE MARKET, BY TYPE

5.1. Introduction

5.2. Insulin Syringe

5.3. Conventional Syringe

5.3.1. Eccentric Tip Syringe

5.3.2. Catheter Tip Syringe

5.3.3. Luer Lock Syringe

6. JAPAN SYRINGE MARKET, BY MATERIAL

6.1. Introduction

6.2. Glass

6.3. Plastic

6.4. Stainless Steel

7. JAPAN SYRINGE MARKET, BY SYRINGE SIZE

7.1. Introduction

7.2. Smaller Volume Syringe

7.3. Larger Volume Syringe

8. COMPETITIVE ENVIRONMENT AND ANALYSIS

8.1. Major Players and Strategy Analysis

8.2. Emerging Players and Market Lucrativeness

8.3. Mergers, Acquisitions, Agreements, and Collaborations

8.4. Vendor Competitiveness Matrix

9. COMPANY PROFILES

9.1. BD

9.2. Nipro 

9.3. TERUMO 

9.4. B. Braun SE

9.5. Teleflex

9.6. ICU Medical, Inc.

9.7. Advin Health Care

9.8. Healthcare Technologies

9.9. Eisai Co., Ltd.

Companies Profiled

BD

Nipro

TERUMO

B. Braun SE

Teleflex

ICU Medical, Inc.

Advin Health Care

Healthcare Technologies

Eisai Co., Ltd.

Related Reports